In-Vivo, Reagent and Regulation - Clinical Research Informer

Global Roundup: EU Approves ViiV’s HIV-1 Drug and More

The Pharma Data

DECEMBER 23, 2020

The agreement includes a £500,000 upfront payment to Avacta which gives Astrea the rights to generate and develop Affimer reagents in-house for affinity separation. In July, ViiV Healthcare, which is based in London, resubmitted the New Drug Application (NDA) for once-monthly dosing of cabotegravir and rilpivirine to the U.S.

Drugs

Drugs Licensing Licensing Vaccination

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

XTalks

OCTOBER 1, 2020

Leaving academia for industry is a route that academic scientists and professors did not traditionally pursue in the past due to perceived differences in skillsets, experiences and even associated stigmas. However, this has since changed, and now, transitioning between academia and industry has become more commonplace. Key Moments.

Scientist

Scientist In-Vitro Research Life Science

Clinical Research Informer

Global Roundup: EU Approves ViiV’s HIV-1 Drug and More

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

Webinars

Stay Connected